Randomized Clinical Trial of Norfloxacin for Shigellosis

Sujit K. BhattacharyaNational Institute of Cholera and Enteric Diseases, Infectious Diseases Hospital, Calcutta, India

Search for other papers by Sujit K. Bhattacharya in
Current site
Google Scholar
PubMed
Close
,
Mihir K. BhattacharyaNational Institute of Cholera and Enteric Diseases, Infectious Diseases Hospital, Calcutta, India

Search for other papers by Mihir K. Bhattacharya in
Current site
Google Scholar
PubMed
Close
,
Phalguni DuttaNational Institute of Cholera and Enteric Diseases, Infectious Diseases Hospital, Calcutta, India

Search for other papers by Phalguni Dutta in
Current site
Google Scholar
PubMed
Close
,
Dipak SenNational Institute of Cholera and Enteric Diseases, Infectious Diseases Hospital, Calcutta, India

Search for other papers by Dipak Sen in
Current site
Google Scholar
PubMed
Close
,
Reeta RasailyNational Institute of Cholera and Enteric Diseases, Infectious Diseases Hospital, Calcutta, India

Search for other papers by Reeta Rasaily in
Current site
Google Scholar
PubMed
Close
,
Amita MoitraNational Institute of Cholera and Enteric Diseases, Infectious Diseases Hospital, Calcutta, India

Search for other papers by Amita Moitra in
Current site
Google Scholar
PubMed
Close
, and
Sudhir C. PalNational Institute of Cholera and Enteric Diseases, Infectious Diseases Hospital, Calcutta, India

Search for other papers by Sudhir C. Pal in
Current site
Google Scholar
PubMed
Close
Restricted access

In a randomized clinical trial, norfloxacin was compared with nalidixic acid in the treatment of acute invasive diarrhea, with particular reference to shigellosis in adults. Of 104 patients studied, 40 were positive for Shigella in stool cultures, of which 22 received norfloxacin and 18 received nalidixic acid. The patients in these two groups were comparable on admission. In the treatment of culture-positive shigellosis cases, the responses to therapy with both drugs were similar, except that the duration of fever, anorexia, and abdominal pain were less in those who received norfloxacin. Norfloxacin appeared to be superior to nalidixic acid in the treatment of shigellosis cases caused by Shigella strains resistant to nalidixic acid.

Save